International Journal of Cancer Management

Published by: Kowsar
Crossmark

The Effect of Testosterone and Estradiol on Renal Function Markers in Two Protocols of Cisplatin Induced Nephrotoxicity Models in Surgically Orchiectomized and Ovariectomized Rats

Bahar Mazaheri 1 , Alireza Samimiat 1 , Mohammad-Sedigh Khosravi 1 , Ardeshir Talebi 1 and Mehdi Nematbakhsh 1 , *
Authors Information
1 Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • International Journal of Cancer Management: 12 (3); e89086
  • Published Online: March 31, 2019
  • Article Type: Research Article
  • Received: January 12, 2019
  • Revised: March 6, 2019
  • Accepted: March 16, 2019
  • DOI: 10.5812/ijcm.89086

To Cite: Mazaheri B, Samimiat A, Khosravi M, Talebi A, Nematbakhsh M. The Effect of Testosterone and Estradiol on Renal Function Markers in Two Protocols of Cisplatin Induced Nephrotoxicity Models in Surgically Orchiectomized and Ovariectomized Rats, Int J Cancer Manag. Online ahead of Print ; 12(3):e89086. doi: 10.5812/ijcm.89086.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3(1):1351-71. doi: 10.3390/cancers3011351. [PubMed: 24212665]. [PubMed Central: PMC3756417].
  • 2. Nematbakhsh M, Pezeshki Z, Eshraghi Jazi F, Mazaheri B, Moeini M, Safari T, et al. Cisplatin-induced nephrotoxicity; protective supplements and gender differences. Asian Pac J Cancer Prev. 2017;18(2):295-314. doi: 10.22034/APJCP.2017.18.2.295. [PubMed: 28345324]. [PubMed Central: PMC5454720].
  • 3. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490-518. doi: 10.3390/toxins2112490. [PubMed: 22069563]. [PubMed Central: PMC3153174].
  • 4. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001;16(5):932-8. doi: 10.1093/ndt/16.5.932. [PubMed: 11328897].
  • 5. Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. J Res Med Sci. 2011;16(11):1389-96. [PubMed: 22973338]. [PubMed Central: PMC3430054].
  • 6. Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol. 2012;25(3):410-7. doi: 10.5301/jn.5000018. [PubMed: 21928232].
  • 7. Nematbakhsh M, Ashrafi F, Pezeshki Z, Fatahi Z, Kianpoor F, Sanei MH, et al. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model? J Nephropathol. 2012;1(3):190-3. doi: 10.5812/nephropathol.8122. [PubMed: 24475415]. [PubMed Central: PMC3886150].
  • 8. Nematbakhsh M, Ashrafi F, Nasri H, Talebi A, Pezeshki Z, Eshraghi F, et al. A model for prediction of cisplatin induced nephrotoxicity by kidney weight in experimental rats. J Res Med Sci. 2013;18(5):370-3. [PubMed: 24174938]. [PubMed Central: PMC3810567].
  • 9. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 2005;67(2):458-66. doi: 10.1111/j.1523-1755.2005.67102.x. [PubMed: 15673293].
  • 10. Nematbakhsh M, Ebrahimian S, Tooyserkani M, Eshraghi-Jazi F, Talebi A, Ashrafi F. Gender difference in Cisplatin-induced nephrotoxicity in a rat model: Greater intensity of damage in male than female. Nephrourol Mon. 2013;5(3):818-21. doi: 10.5812/numonthly.10128. [PubMed: 24282792]. [PubMed Central: PMC3830908].
  • 11. Nematbakhsh M, Talebi A, Nasri H, Safari T. Some evidence for sex-based differences in cisplatin-induced nephrotoxicity in rats. Clin Experiment Med Lett. 2012;53:29-32.
  • 12. Pezeshki Z, Nematbakhsh M, Nasri H, Talebi A, Pilehvarian AA, Safari T, et al. Evidence against protective role of sex hormone estrogen in Cisplatin-induced nephrotoxicity in ovarectomized rat model. Toxicol Int. 2013;20(1):43-7. doi: 10.4103/0971-6580.111568. [PubMed: 23833437]. [PubMed Central: PMC3702126].
  • 13. Rostami B, Nematbakhsh M, Pezeshki Z, Talebi A, Sharifi MR, Moslemi F, et al. Effect of testosterone on Cisplatin-induced nephrotoxicity in surgically castrated rats. Nephrourol Mon. 2014;6(5). e21546. doi: 10.5812/numonthly.21546. [PubMed: 25695037]. [PubMed Central: PMC4318011].
  • 14. Daniel G, Hahn K, Bravo L, Legendre A. The effect of a single therapeutic dose of cisplatin on GFR in dogs. Oncol Rep. 1997;4(1):153-6. doi: 10.3892/or.4.1.153. [PubMed: 21590032].
  • 15. Stakisaitis D, Dudeniene G, Jankunas RJ, Grazeliene G, Didziapetriene J, Pundziene B. Cisplatin increases urinary sodium excretion in rats: Gender-related differences. Medicina (Kaunas). 2010;46(1):45-50. doi: 10.3390/medicina46010008. [PubMed: 20234163].
  • 16. Pezeshki Z, Maleki M, Talebi A, Nematbakhsh M. Age and gender related renal side effects of cisplatin in animal model. Asian Pac J Cancer Prev. 2017;18(6):1703-5. doi: 10.22034/APJCP.2017.18.6.1703. [PubMed: 28670892].
  • 17. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev. 1999;99(9):2451-66. doi: 10.1021/cr980420v. [PubMed: 11749486].
  • 18. Esteban-Fernandez D, Verdaguer JM, Ramirez-Camacho R, Palacios MA, Gomez-Gomez MM. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J Anal Toxicol. 2008;32(2):140-6. doi: 10.1093/jat/32.2.140. [PubMed: 18334097].
  • 19. Soni KK, Kim HK, Choi BR, Karna KK, You JH, Cha JS, et al. Dose-dependent effects of cisplatin on the severity of testicular injury in Sprague Dawley rats: Reactive oxygen species and endoplasmic reticulum stress. Drug Des Devel Ther. 2016;10:3959-68. doi: 10.2147/DDDT.S120014. [PubMed: 28003740]. [PubMed Central: PMC5161341].
  • 20. Zhang IF, Li T, Hu XC. Toxicity profile of cisplatin given at one full dose versus three divided doses for three consecutive days. J Clin Oncol. 2016;34(15_supp).
  • 21. Ahmadzadeh A, Shahbazian H, Safapour N, Tulabi M, Zandifar S. Comparison between the effects of one-day treatment regimen with cisplatin on renal function and various biochemical parameters in patients with gastric and lung cancer compared with two-days divided cisplatin treatment regimen. J Renal Inj Prev. 2015;4(3):87-91. doi: 10.12861/jrip.2015.17. [PubMed: 26468480]. [PubMed Central: PMC4594219].
  • 22. Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med. 2007;43(5):645-57. doi: 10.1016/j.freeradbiomed.2007.04.026. [PubMed: 17664129]. [PubMed Central: PMC2041919].
  • 23. Mazaheri S, Nematbakhsh M, Bahadorani M, Pezeshki Z, Talebi A, Ghannadi AR, et al. Effects of fennel essential oil on cisplatin-induced nephrotoxicity in ovariectomized rats. Toxicol Int. 2013;20(2):138-45. doi: 10.4103/0971-6580.117256. [PubMed: 24082507]. [PubMed Central: PMC3783680].
  • 24. Garcia MM, Acquier A, Suarez G, Gomez NV, Gorostizaga A, Mendez CF, et al. Cisplatin inhibits testosterone synthesis by a mechanism that includes the action of reactive oxygen species (ROS) at the level of P450scc. Chem Biol Interact. 2012;199(3):185-91. doi: 10.1016/j.cbi.2012.08.012. [PubMed: 22940207].
  • 25. Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem. 2004;279(50):52282-92. doi: 10.1074/jbc.M407629200. [PubMed: 15358759].
  • 26. Verzola D, Gandolfo MT, Salvatore F, Villaggio B, Gianiorio F, Traverso P, et al. Testosterone promotes apoptotic damage in human renal tubular cells. Kidney Int. 2004;65(4):1252-61. doi: 10.1111/j.1523-1755.2004.00497.x. [PubMed: 15086464].
  • 27. Mooradian AD. Antioxidant properties of steroids. J Steroid Biochem Mol Biol. 1993;45(6):509-11. doi: 10.1016/0960-0760(93)90166-T. [PubMed: 8518206].
  • 28. Beleh MA, Lin YC, Brueggemeier RW. Estrogen metabolism in microsomal, cell, and tissue preparations of kidney and liver from Syrian hamsters. J Steroid Biochem Mol Biol. 1995;52(5):479-89. doi: 10.1016/0960-0760(95)00003-I. [PubMed: 7748813].
  • 29. Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, Ashrafi F, Nasri H, Talebi A, et al. Vitamin E, vitamin C, or losartan is not nephroprotectant against cisplatin-induced nephrotoxicity in presence of estrogen in ovariectomized rat model. Int J Nephrol. 2012;2012:284896. doi: 10.1155/2012/284896. [PubMed: 23056943]. [PubMed Central: PMC3463913].
  • 30. Roy D, Liehr JG. Target organ-specific inactivation of drug metabolizing enzymes in kidney of hamsters treated with estradiol. Mol Cell Biochem. 1992;110(1):31-9. doi: 10.1007/BF02385003. [PubMed: 1315925].
  • 31. Butterworth M, Lau SS, Monks TJ. 2-Hydroxy-4-glutathion-S-yl-17beta-estradiol and 2-hydroxy-1-glutathion-S-yl-17beta-estradiol produce oxidative stress and renal toxicity in an animal model of 17beta-estradiol-mediated nephrocarcinogenicity. Carcinogenesis. 1998;19(1):133-9. doi: 10.1093/carcin/19.1.133. [PubMed: 9472704].
  • 32. Song JY, Kim MJ, Jo HH, Hwang SJ, Chae B, Chung JE, et al. Antioxidant effect of estrogen on bovine aortic endothelial cells. J Steroid Biochem Mol Biol. 2009;117(1-3):74-80. doi: 10.1016/j.jsbmb.2009.07.006. [PubMed: 19635556].
  • 33. Mann V, Huber C, Kogianni G, Collins F, Noble B. The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone. 2007;40(3):674-84. doi: 10.1016/j.bone.2006.10.014. [PubMed: 17174166].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments